Quest Diagnostics Incorporated

DGX Healthcare Diagnostics & Research

Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 14.7%, free cash flow grew 5.28% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

235.00 4.15 −1.74%
Market cap
$26.4B
P/E
24.6×
Fwd P/E
20.8×
Dividend yield
1.44%
F-score
8/9
Altman Z
3.15
Beneish M
−2.65
Dividend safety
85/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
14.03% 13.95% 14.10% 13.64%

+8 more TTM periods

Piotroski F-Score
8 8 7 8
ROA
6.43% 6.28% 6.10% 5.97%
ROIC
7.94% 7.78% 7.81% 7.63%
Return on Tangible Assets
32.31% 39.57% 42.90% 39.87%
Average Days of Receivables
52.60 51.36 46.57 48.98
Free Cash Flow per Share
12.15 12.05 12.24 12.44
Free Cash Flow
1,349.00 1,326.00 1,359.00 1,393.00
Other line items

Show all line items

Columns are period end dates